The EU Commission reviews the merger between two biotech company specialised in genomic sequencing (Illumina / Grail)

The European Commission opens a review of Illumina's acquisition of Grail under the procedure of Article 22 of the 2004 Merger Regulation*Background Following the referral request submitted by the Autorité de la concurrence, which was joined by several Member States of the European Economic Area (Belgium, Greece, Iceland, the Netherlands, Norway), the Commission has decided to open an examination on Illumina's acquisition of Grail’s transaction (see press release of 20 April 2021). This is the first time since Margrethe Vestager’s announcement of her new approach in terms of merger control of "below the threshold" transactions under Article 22 of Regulation 139/2004, that the Commission will examine a merger transaction that was not submitted to a mandatory notification in terms of

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

Quotation

French Competition Authority, The EU Commission reviews the merger between two biotech company specialised in genomic sequencing (Illumina / Grail), 20 April 2021, e-Competitions June 2021, Art. N° 100379

Visites 145

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues